Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/qjmed/hcs137 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Article Synopsis
- * The study highlights three patients with metastatic pituitary lesions linked to primary cancers of the breast, lung, and kidney, all of whom had surgical treatment at an endocrinology research center.
- * Symptoms included panhypopituitarism and chiasmal syndrome, with varying outcomes; two patients experienced disease progression while one maintained a stable condition after surgery.
Hepatopulmonary syndrome secondary to metabolic associated fatty liver disease in childhood - novel treatment with growth hormone replacement therapy: a case report and systematic review of literature.
Front Endocrinol (Lausanne)
November 2024
Department of Pediatrics, Seoul National University College of Medicine, Seoul, Republic of Korea.
Objective: Hepatopulmonary syndrome (HPS) is a rare complication of metabolic associated fatty liver disease (MAFLD) occurring subsequent to hypopituitarism, often developing after resection of hypothalamic or pituitary tumors. The aim of this study is to report an illustrative case of an HPS patient who was successfully treated with growth hormone replacement therapy, without liver transplantation which is conventionally regarded as the only treatment option. Additionally, we conducted a comprehensive review of published case reports of HPS in the pediatric population.
View Article and Find Full Text PDFPurpose: Patients with transfusion-dependent β-thalassemia (TDT) have reduced levels of β-globin, leading to ineffective erythropoiesis and iron overload. Patients with TDT depend on regular red blood cell transfusions (RBCTs) and iron chelation therapy for survival and management of disease- and treatment-related clinical complications. This study describes the clinical and economic burden in patients with TDT in England.
View Article and Find Full Text PDFThe clinical and genetic aspects of six individuals with variants and isolated growth hormone deficiency type II.
Front Endocrinol (Lausanne)
October 2024
Department of Endocrinology, Genetics and Metabolism, Fuzhou Children's Hospital of Fujian Medical University, Fuzhou, Fujian, ;China.
Article Synopsis
- Isolated growth hormone deficiency type II (IGHD II) is a genetic condition leading to low growth hormone production, resulting in stunted growth and lower IGF-1 levels in affected individuals.
- The study examined six children from Chinese families with IGHD II, revealing various genetic variants associated with the condition, including several novel mutations.
- After starting growth hormone replacement therapy, the children showed significant improvement in height, with an average increase of 1.21 SDS in the first six months and 1.79 SDS in the first year of treatment.
Wrong Tissue at the Wrong Place: A Rare Case of Hypopituitarism Secondary to Metastatic Renal Cell Carcinoma.
Cureus
July 2024
Diabetes, Endocrinology, and Metabolism, University of Minnesota, Minneapolis, USA.
Metastasis to the pituitary gland is a very rare occurrence. The most common primary cancer that metastasizes to the pituitary are breast cancer and lung cancer. Most of the pituitary metastases are asymptomatic.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!